Back to Authors

Gounari, Fotini

0000-0003-2936-066X

Mayo Clinic

Department of Immunology, Mayo Clinic, Phoenix, Arizona, United States, USA.

Citations 12

Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner
Osman, Abu , Gurish, Michael F. , Dennis, Kristen L., Blatner, Nichole R., Pezeshki, Abdulmohammad , McNagny, Kelly M. , Cheroutre, Hilde , Gounari, Fotini , Khazaie, Khashayarsha , Saadalla, Abdulrahman M, McNagny, Kelly M , Khazaie, Khashayarsha , Saadalla, Abdulrahman , Gounari, Fotini

Proceedings of the National Academy of Sciences | February 2, 2018 | Volume: 115 | Issue: 7 | Pages: 1588-1592

10.1073/pnas.1716804115 Get It

Significance We show that distinct subsets of mast cells (MCs) expand with sequential oncogenic events in small bowel cancer. Mucosal mast cells (MMCs) previously detected early during Trichinella spiralis infection expand in adenomatous polyps in an IL-10–dependent manner. Connective tissue mast cells (CTMCs), earlier shown to expand during the resolution of inflammation following clearance of T. spiralis, are independent of IL-10 and associate with the transition of polyps to adenocarcinoma. IL-33 upregulates the CTMC lineage-specific protease murine mast cell protease 6 (mMCP6). Ablation of mMCP6 attenuates tumor growth. Thus, tissue sentinel cells respond to oncogenic events and cellular transformation in effect to help promote cancer. Delineating the types of MCs present at various stages of disease offers actionable cellular targets for therapeutic intervention in disease progression.
T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Dennis, Kristen L., Blatner, Nichole R., Wang, Shuya , Venkateswaran, Vysak, Gounari, Fotini , Cheroutre, Hilde , Roers, Axel , Egilmez, Nejat K. , Khazaie, Khashayarsha , Saadalla, Abdulrahman , Weaver, Casey T. , Gounari, Fotini

Cancer Immunology Research | April 8, 2015 | Volume: 3 | Issue: 7 | Pages: 806-814

10.1158/2326-6066.cir-14-0169 Get It

Abstract IL10 is attributed with immune-suppressive and anti-inflammatory properties, which could promote or suppress cancer in the gastrointestinal tract. Loss of IL10 exacerbates colonic inflammation, leading to colitis and cancer. Consistent with this, transfer of IL10-competent regulatory T cells (Treg) into mice with colitis or hereditary polyposis protects against disease, while IL10-deficient mice are predisposed to polyposis with increased colon polyp load. Little is known about the protective or pathogenic function of IL10 in cancers of the small intestine. We found CD4+ T cells and CD4+ Foxp3+ Tregs to be the major sources of IL10 in the small intestine and responsible for the increase in IL10 during polyposis in the APCΔ468 mouse model of hereditary polyposis. Targeted ablation of IL10 in T cells caused severe IL10 deficiency and delayed polyp growth. However, these polyps progressively lost cytotoxic activity and eventually progressed to cancer. Several observations suggested that the effect was due to the loss of IFNγ-dependent immune surveillance. IL10-incompetent CD4+ T cells failed to secrete IFNγ when stimulated with polyp antigens and were inefficient in T-helper-1 (TH1) commitment. By contrast, the TH17 commitment was unaffected. These findings were validated using mice whose T cells overexpress IL10. In these mice, we observed high intra-polyp cytotoxic activity and attenuation of polyposis. Thus, expression of IL10 by T cells is protective and required for immune surveillance in the small intestine. Cancer Immunol Res; 3(7); 806–14. ©2015 AACR.